解毒凉血利湿方治疗乙型肝炎急性加重期的疗效及对患者肝功能的影响

摘要

Objective To observe the curative effect of Jiedu Liangxue Lishi Decoction for patients with acute exacerbation of hepatitis B,and to explore its influence on liver function.Methods 112 patients with acute exacerbation of hepatitis B treated at our hospital from January,2015 to January,2018 were randomly divided into a study group and a control group,56 cases for each group.The control group were treated with conventional western medicine,while the study group with Jiedu Liangxue Lishi Decoction and western medicine.The indicators of liver function,blood coagulation function,clinical efficacy,and complications were compared between the two groups before and after the treatment.Results The total effective rate was significantly higher in the study group than in the control group (98.21％ vs.76.79％,P ＜ 0.05).The incidence of adverse reactions was significantly lower in the study group than in the control group (5.36％ vs.26.79％,P ＜ 0.05).Before the treatment,there were no statistical differences in the levels of TBIL,AST,ALT,ALB,PT,and PTA between these two groups (all P ＞ 0.05).After the treatment,the levels of TBIL,AST,ALT,ALB,PT,and PTA were (22.35±1.73) μmol/L,(44.22±2.25) U/L,(28.33±1.49) U/L,(38.51±2.04)g/L,(12.34±1.07)s,and (99.41±10.27)％ in the study group,which were better than those in the control group,with statistical differences (all P ＜ 0.05).Conclusions Jiedu Liangxue Lishi Decoction in the treatment of patients with acute exacerbation of hepatitis B has a definite curative effect.It can significantly improve the patients' liver function and coagulation function and reduce the incidence of complications.It is worth being generalized.%目的 观察解毒凉血利湿方治疗乙型肝炎急性加重期的疗效,并探讨对患者肝功能的影响.方法 选择2015年1月至2018年1月在本院治疗的112例乙型肝炎急性加重期患者,应用抽签法随机分为研究组和对照组,各56例.对照组患者给予常规西药治疗,研究组患者在对照组治疗基础上给予解毒凉血利湿方治疗.比较两组患者治疗前后的肝功能指标、凝血功能水平,以及治疗后的临床疗效及不良反应发生情况.结果 研究组临床治疗总有效率98.21％,高于对照组76.79％,差异有统计学意义(P＜0.05);研究组并发症发生率5.36％,低于对照组26.79％,差异有统计学意义(P＜0.05);治疗前,两组患者TBIL、AST、ALT水平比较,差异无统计学意义(P＞0.05);治疗后,研究组TBIL、AST、ALT水平分别为(22.35±1.73) μmol/L、(44.22±2.25) U/L、(28.33±1.49)U/L,明显低于对照组,ALB水平(38.51±2.04)g/L,明显高于对照组,差异均有统计学意义(均P＜0.05);治疗前,两组患者PT、PTA水平比较,差异均无统计学意义(均P＞ 0.05);治疗后,研究组PT为(12.34±1.07)s,明显低于对照组,PTA为(99.41±10.27)％,明显高于对照组,差异均有统计学意义(均P＜0.05).结论 应用解毒凉血利湿方治疗乙型肝炎急性加重期患者疗效确切,可明显改善患者肝功能和凝血功能,降低并发症发生率,值得推广使用.